Abstract
A quantitative, alternative pathway (AP) hemolytic assay for human complement component C3 has been developed. This AP-C3 assay is inexpensive, rapid, simple, reproducible and insensitive to C3 degradation products. The AP-C3 assay uses rabbit erythrocytes as complement activator and methylamine-treated plasma, depleted of C3 and C4, as complement source. Rabbit erythrocyte sensitivity varies little from batch to batch, and remains unaltered for at least one month in Alsever's solution. Methylamine plasma may be stored at -20 degrees C for 3 months. AP-C3 lysis of 5-25% of erythrocytes is complete in 20 min and does not change subsequently. The AP-C3 assay is optimally stable at 2 mM Mg2+, 5 mM EGTA and at 5 X 10(7) erythrocytes/ml, yet insensitive to at least 20% deviation in these concentrations. The AP-C3 assay is specific to functional C3 and well suited for determination in plasma samples and during C3 preparation. Adding excessive amounts of C3c or plasma components other than C3 does not change the hemolytic response. The level of native C3 in plasma from 14 donors relative to a reference plasma pool ranged from 0.78 to 1.23. The standard deviation of relative C3 determinations did not exceed 2%.
References
Jan 1, 1978·Journal of Biological Standardization·C B ReimerS G Anderson
Dec 1, 1978·The Journal of Experimental Medicine·R D Schreiber, H J Müller-Eberhard
Jan 1, 1980·Advances in Immunology·H J Müller-Eberhard, R D Schreiber
Oct 1, 1980·The Biochemical Journal·L G Crossley, R R Porter
Sep 14, 1981·FEBS Letters·E SimR B Sim
Oct 1, 1980·The Journal of Experimental Medicine·M K Pangburn, H J Müller-Eberhard
Sep 1, 1981·The Journal of Experimental Medicine·M K PangburnH J Müller-Eberhard
Oct 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·B F TackJ W Prahl
Dec 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·S K LawR P Levine
Jul 21, 1981·Biochemistry·D E IsenmanM K Pangburn
Jan 1, 1980·Molecular Immunology·R A Harrison, P J Lachmann
Citations
Sep 15, 1984·Experientia·J ZídkováJ Stránsky
Jun 21, 1989·Journal of Immunological Methods·L TosicR P Taylor
Aug 15, 1989·Journal of Immunological Methods·C W Van den BergP J Capel
Oct 19, 1990·Journal of Immunological Methods·C W Van den BergH Van Dijk
Feb 15, 1991·Journal of Immunological Methods·C W Van den BergH Van Dijk
Feb 3, 1993·Journal of Immunological Methods·V R MuzykantovA L Klibanov
Aug 1, 1985·Molecular Immunology·N Behrendt
Oct 1, 1987·Molecular Immunology·N BehrendtC Koch
Jul 1, 1991·Molecular Immunology·C D BarroM G Colomb
Jul 1, 1993·Molecular Immunology·C A Rey-MilletM G Colomb
Jun 1, 1987·Veterinary Immunology and Immunopathology·A Mhatre, W P Aston
May 1, 1992·Veterinary Immunology and Immunopathology·G VenugopalM P Bansal
Sep 1, 1993·Veterinary Immunology and Immunopathology·J S Boschwitz, J F Timoney
Sep 1, 1999·Immunology·M L GrattoneP N Marche
Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·C W van den BergH Van Dijk
Nov 1, 1991·Scandinavian Journal of Immunology·M B VilliersM G Colomb
Dec 1, 1989·Parasitology·F PeyronP Ambroise-Thomas
Mar 23, 1987·FEBS Letters·J A SchifferliJ P Paccaud
May 1, 1985·Analytical Biochemistry·M PlougV Barkholt
Jul 1, 1985·European Journal of Immunology·G KraalH Van Dijk
Oct 1, 1988·Journal of Immunogenetics·F DieliA Salerno
Feb 18, 2003·European Journal of Clinical Investigation·J-M HamentT F W Wolfs
Jul 1, 1994·European Journal of Immunology·L SantoroM G Colomb
Jan 19, 2012·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Joanna-Marie HowesAngela M Carter
Aug 17, 2014·Molecular Cancer Therapeutics·Houbin WangJun Gu
Apr 29, 1998·Journal of Chromatography. a·G Houen, I Svendsen
Dec 1, 1993·Infection and Immunity·J CroizeM G Colomb
Sep 1, 1994·Infection and Immunity·E MattssonA Fleer
Aug 24, 1987·Journal of Immunological Methods·M K Pangburn